


App. No.: 10/801,443  
Art Unit: 1624

**Amendments to the Claims:**


This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A process for preparation of Cefprozil of formula (I)




in the form of a monohydrate, the process comprising: reacting a  
condensing a mixed acid anhydride of  $\alpha$ -amino-p-hydroxy phenylacetic acid of formula (III)



wherein R<sup>1</sup> is an alkyl or an aryl group, and R<sup>2</sup> is methyl or ethyl,

with a protected 7-amino-3-(propen-1-yl)-3-cephem-4-carboxylic acid of formula (VII)

App. No.: 10/801,443  
Art Unit: 1624



wherein  $R^3$  and  $R^4$  are protective groups, and  $R$  is propen-1-yl,  
followed by hydrolysis, isolation and purification to give Cefprozil of formula (I) in the form of  
a monohydrate in high yield and purity, substantially free of impurities,  
wherein the mixed anhydride of formula (III) is prepared by a process comprising the steps  
of


(a) adding a suitable acylating agent and a base to a mixture of an inert organic solvent and a  
polar aprotic solvent at a temperature in the range of 0° to 40°C;

(b) cooling the solution to a temperature in the range of -70° to -30°C;

(c) addition of Dane salt of an  $\alpha$ -amino-p-hydroxy phenyl acetic acid to the cooled solution and  
agitation at a temperature in the range of -70° to -30°C.


2. (Canceled)

3. (Currently Amended) A process as in claim 1A process for preparation of Cefprozil of  
formula (I)




App. No.: 10/801,443  
 Art Unit: 1624

in the form of a monohydrate, the process comprising:  
condensing a mixed acid anhydride of  $\alpha$ -amino-p-hydroxy phenyl acetic acid of formula (III)



wherein R<sup>1</sup> is an alkyl or an aryl group and R<sup>2</sup> is methyl or ethyl,  
with a protected 7-amino-3-(propen-1-yl)-3-cephem-4-carboxylic acid of formula (VII)




wherein R<sup>3</sup> and R<sup>4</sup> are protective groups, R is propen-1-yl,  
followed by hydrolysis, isolation and purification to give Cefprozil of formula (I) in the form  
of a monohydrate,  
wherein the mixed anhydride of an  $\alpha$ -amino-p-hydroxy phenylacetic acid of formula (III) is  
prepared by a process comprising the steps of

- (a) adding [[an]] a suitable acylating agent and a base to an inert organic solvent at a temperature in the range of 0° to 40°C, preferably 20° to 25°C;


App. No.: 10/801,443  
 Art Unit: 1624

- (b) cooling the solution to a temperature in the range of -70° to -30°C, preferably -35°C to -50°C;
- (c) addition of Dane salt of an  $\alpha$ -amino-p-hydroxy phenylacetic acid to the cooled solution and agitation at a temperature in the range of -70° to -30°C, preferably -35°C to -50°C;
- (d) addition of a polar aprotic solvent to the above solution and agitation at a temperature in the range of -70° to -30°C, preferably -35°C to -50°C.

4. (Currently Amended) A process as in claim 1 wherein the protected 7-amino-3-(propen-1-yl)-3-cephem-4-carboxylic [7-APCA] 7-APCA of formula (VII) used



is such that R<sup>3</sup> and R<sup>4</sup> are each a tri alkylsilyl group, and represented by formula VI.



and R is propen-1-yl.

5. (Currently Amended) A process according to claim [[2]] 1, wherein the inert organic solvent employed in step [[i]](a) is selected from the group consisting of methylene chloride,

App. No.: 10/801,443  
Art Unit: 1624

tetrahydrofuran, chloroform, diethyl ether, chlorotetane, acetonitrile, trichloroethylene, and ethyl acetate.

6. (Currently Amended) A process according to claim 3, wherein the inert organic solvent employed in step [[i]](a) is selected from the group consisting of methylene chloride, tetrahydrofuran, chloroform, diethyl ether, ~~chlorotetane~~ chloroethane, acetonitrile, trichloroethylene, and ethyl acetate.

7. (Currently Amended) A process according to claim [[2]] 1, wherein the polar aprotic solvent employed in step [[i]](a) is selected from the group consisting of N, N-dimethyl formamide, acetone, acetonitrile, dimethyl sulphoxide, and dimethyl acetamide. ~~N,N-dimethyl formamide is the preferred polar aprotic solvent.~~

8. (Currently Amended) A process according to claim 3, wherein the polar aprotic solvent employed in step [[i]](a) is selected from the group consisting of N, N-dimethyl formamide, acetone, acetonitrile, dimethyl sulphoxide, and dimethyl acetamide. ~~N,N-dimethyl formamide is the preferred polar aprotic solvent.~~

9. (Currently Amended) A process according to claim [[2]] 1, wherein the suitable acylating agent[[s]] employed in step [[i]](a) is an ester of an chosen from reactive forms of aliphatic, alicyclic, or aromatic acid[[s]], or a halogenide of an aliphatic, alicyclic, or aromatic acid such as chloroformic acid, benzoic acid, pivalic acid and 2-ethylhexanoic acid. The reactive forms of these acids include their esters such as ethyl chloroformate, isobutyl chloroformate and their halogenides like pivaloyl chloride, 2-ethyl hexanoyl chloride and benzoyl chloride, the preferred acylating agent being ethyl chloroformate.

10. (Currently Amended) A process according to claim 3, wherein the suitable acylating agent[[s]] employed in step [[i]](a) is an ester of an chosen from reactive forms of aliphatic, alicyclic, or aromatic acid[[s]], or a halogenide of an aliphatic, alicyclic, or aromatic acid such as

App. No.: 10/801,443  
Art Unit: 1624

chloroformic acid, benzoic acid, pivalic acid and 2-ethylhexanoic acid. The reactive forms of these acids include their esters such as ethyl chloroformate, isobutyl chloroformate and their halogenides like pivaloyl chloride, 2-ethyl hexanoyl chloride and benzoyl chloride, the preferred acylating agent being ethyl chloroformate.

11. (Currently Amended) A process according to claim [[2]] 1, wherein the base employed in step [[i]](a) is selected from the group consisting of triethylamine, picoline, N-methylmorpholine, N, N-dimethylbenzylamine, lutidine, N, N-dimethyl-4-aminopyridine, and N, N-dicyclohexylamine, the preferred base being N-methylmorpholine.
12. (Currently Amended) A process according to claim 3, wherein the base employed in step [[i]] (a) is selected from the group consisting of triethylamine, picoline, N-methylmorpholine, N, N-dimethylbenzylamine, lutidine, N, N-dimethyl-4-aminopyridine, and N, N-dicyclohexylamine, the preferred base being N-methylmorpholine.
13. (Currently Amended) A process according to claim [[2]] 1, wherein the acylating agent employed in step [[i]](a) is employed preferably in the ~~range~~ molar ratio of [[1]] 1.0 to 1.5 moles per mole of Dane salt.
14. (Currently Amended) A process according to claim 3, wherein the acylating agent employed in step [[i]] (a) is employed preferably in the ~~range~~ molar ratio of [[1]] 1.0 to 1.5 moles per mole of Dane salt.
15. (Currently Amended) A process according to claim [[2]] 1, wherein the base employed in step [[i]](a) is employed preferably in the ~~range~~ molar ratio of 0.02 to 0.04 moles per mole of the Dane salt.
16. (Currently Amended) A process according to claim 3, wherein the base employed in step [[i]](a) is employed preferably in the ~~range~~ molar ratio of 0.02 to 0.04 moles per mole of the Dane salt.

App. No.: 10/801,443  
Art Unit: 1624

17. (Currently Amended) A process according to claim [[2]] 1 wherein the temperature in step [[i]](a) is preferably in the range of 20° to 25°C.

18. (Currently Amended) A process according to claim 3 wherein the temperature in step [[i]](a) is preferably in the range of 20° to 25°C.

19. (Currently Amended) A process according to claim [[2]] 1 wherein the Dane salt is preferably sodium or potassium D-N- (1-methoxycarbonylpropene-2-yl)- $\alpha$ -amino-p-hydroxyphenyl acetate or sodium or potassium D-N- (1-ethoxycarbonylpropene-2-yl)- $\alpha$ -amino-p-hydroxyphenyl acetate.

20. (Currently Amended) A process according to claim 3 wherein the Dane salt is preferably sodium or potassium D-N- (1-methoxycarbonylpropene-2-yl)- $\alpha$ -amino-p-hydroxyphenyl acetate or sodium or potassium D-N- (1-ethoxycarbonylpropene-2-yl)- $\alpha$ -amino-p-hydroxyphenyl acetate.

21. (Currently Amended) A process according to claim [[2]] 1 wherein the temperature in step [[i](c)] (b) is preferably in the range of -35°C to -50°C.

22. (Currently Amended) A process according to claim 3 wherein the temperature in step [[i](c)] (b) is preferably in the range of -35°C to -50°C.

23. (Currently Amended) A process according to claim [[2]] 1 wherein the temperature in step [[i](d)] (c) is preferably in the range of -35°C to -50°C.

24. (Currently Amended) A process according to claim 3 wherein the temperature in step [[i](d)] (c) is preferably in the range of -35°C to -50°C.


25. (Currently Amended) A process according to claim 1 wherein the mixed acid anhydride is condensed with protected 7-amino-3- (propen-1-yl)-3-cephem-4-carboxylic acid 7-APCA at a temperature preferably in the range of -90° to -30°.

App. No.: 10/801,443  
Art Unit: 1624

26. (Currently Amended) A process according to claim [[1]] 25 wherein the mixed acid anhydride is condensed with protected 7-amino-3- (propen-1-yl)-3-cephem-4-carboxylic acid 7-APCA at a temperature ~~most preferably~~ in the range of -50° to -40°C.

27. (Currently Amended) A process according to claim [[25]] 38 wherein the mixed acid anhydride is condensed with protected 7-amino-3- (propen-1-yl)-3-cephem-4-carboxylic acid 7-APCA at a temperature ~~most preferably~~ in the range of -50° to -40°C.


28. (Currently Amended) A silylated 7-amino-3- (propen-1-yl)-3-cephem-4-carboxylic acid ~~compound of~~ according to claim 4, is of formula (VI)[[.]]



29-30. (Canceled)

31. (New) A process according to claim 3 wherein the protected 7-amino-3- (propen-1-yl)-3-cephem-4-carboxylic [7-APCA] of formula (VII) used


App. No.: 10/801,443  
 Art Unit: 1624



is such that R<sup>3</sup> and R<sup>4</sup> are each tri alkylsilyl group, and R is propen-1-yl.

32. (New) A process according to claim 7, wherein the polar aprotic solvent is N, N-dimethyl formamide.
33. (New) A process according to claim 8, wherein the polar aprotic solvent is N, N-dimethyl formamide.
34. (New) A process according to claim 41, wherein the suitable acylating agent is ethyl chloroformate.
35. (New) A process according to claim 42, wherein the suitable acylating agent is ethyl chloroformate.
36. (New) A process according to claim 11, wherein the base is N-methylmorpholine.
37. (New) A process according to claim 12, wherein the base is N-methylmorpholine.
38. (New) A process according to claim 3, wherein the mixed acid anhydride is condensed with protected 7-amino-3-(propen-1-yl)-3-cephem-4-carboxylic acid at a temperature in the range of -90° to -30°C.
39. (New) A silylated 7-amino-3- (propen-1-yl)-3-cephem-4-carboxylic acid according to claim 31, is of formula (VI)

App. No.: 10/801,443  
Art Unit: 1624



40. (New) A process according to claim 3 wherein the temperature in step (d) is in the range of  $-35^{\circ}\text{C}$  to  $-50^{\circ}\text{C}$ .

41. (New) A process according to claim 9 wherein the suitable acylating agent is selected from the group consisting of chloroformic acid, benzoic acid, pivalic acid, 2-ethylhexanoic acid, ethyl chloroformate, isobutyl chloroformate, pivaloyl chloride, 2-ethyl-hexanoyl chloride, and benzoyl chloride.

42. (New) A process according to claim 10 wherein the suitable acylating agent is selected from the group consisting of chloroformic acid, benzoic acid, pivalic acid, 2-ethylhexanoic acid, ethyl chloroformate, isobutyl chloroformate, pivaloyl chloride, 2-ethyl-hexanoyl chloride, and benzoyl chloride.